Three studies stratified by HRT use [31,32,35], two of which suggest an elevated risk of postmenopausal breast cancer for non-users of HRT with high CRP levels (highest versus lowest tertile and highest versus lowest quartile, respectively: HR 2.08, 95% CI: 1.16, 3.76 [31] and HR 1.63, 95% CI: 0.95, 2.80 [32]), but not for users of HRT (HR 1.32, 95% CI: 0.57, 3.05 [31] and HR 0.90, 95% CI: 0.53, 1.53 [32]). The gene discussed is CRP; the disease is breast carcinoma.